Patents by Inventor Lynn E. Murry
Lynn E. Murry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6093561Abstract: The invention provides a human lysophospholipase (NHLP) and polynucleotides which identify and encode NHLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of NHLP.Type: GrantFiled: December 18, 1998Date of Patent: July 25, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah, Lynn E. Murry
-
Patent number: 6090377Abstract: The present invention provides novel monocyte activating cytokine (MAC) and a polynucleotide encoding MAC. The invention also provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MAC. The invention also provides for the production and use of substantially purified MAC in pharmaceutical compositions for the treatment of cancer and disease of the immune system. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding MAC and antibodies which specifically bind to MAC.Type: GrantFiled: July 28, 1998Date of Patent: July 18, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Roger Coleman, Janice Au-Young, Lynn E. Murry
-
Patent number: 6060239Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel cellubrevins (cb). The present invention also provides for antisense molecules to the nucleotide sequences which encode cbs, expression vectors for the production of purified CBs, antibodies capable of binding specifically to CBs, hybridization probes or oligonucleotides for the detecting the induction of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CBs, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CBs.Type: GrantFiled: March 22, 1996Date of Patent: May 9, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Susan G. Stuart, Phillip R. Hawkins, Jeffrey J. Seilhamer, Lynn E. Murry
-
Patent number: 6054290Abstract: The present invention provides a human vesicle binding protein (MVBP) and polynucleotides which identify and encode MVBP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing MVBP and for treating or preventing disorders associated with expression of MVBP.Type: GrantFiled: May 15, 1997Date of Patent: April 25, 2000Assignee: Incyte Pharamaceuticals, Inc.Inventors: Olga Bandman, Phillip R. Hawkins, Lynn E. Murry
-
Patent number: 6033869Abstract: The present invention provides a human cytokine/steroid receptor protein (CYSTAR) and polynucleotides which identify and encode CYSTAR. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of CYSTAR, as well as diagnostic assays.Type: GrantFiled: March 20, 1997Date of Patent: March 7, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Surya K. Goli, Jennifer L. Hillman, Lynn E. Murry
-
Patent number: 6015883Abstract: The present invention provides a polynucleotide (PTEC) isolated from a prostate cDNA library which identifies and encodes a novel human rantes homolog PTEC (prostate expressed chemokine). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PTEC. The invention also provides for the therapeutic use of purified PTEC in the treatment of immune deficiency diseases, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of conditions or diseases associated with the expression of PTEC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, or fragments thereof, or antibodies which specifically bind to the polypeptide.Type: GrantFiled: September 24, 1997Date of Patent: January 18, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Olga Bandman, Lynn E. Murry
-
Patent number: 6004792Abstract: The invention provides a new human lysophospholipase (IHLP) and polynucleotides which identify and encode IHLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating inflammation and disorders associated with expression of IHLP.Type: GrantFiled: December 17, 1998Date of Patent: December 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley, Lynn E. Murry
-
Patent number: 6001632Abstract: The present invention provides a polynucleotide (pdih) the partial sequence for which was initially isolated from a lung cDNA library and which identifies and encodes a novel human protein disulfide isomerase (PDIH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PDIH. The invention also provides for the use of purified PDIH and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the abnormal expression of PDIH. Additionally, the invention provides for the use of antisense molecules to pdih or inhibitors of PDIH in pharmaceutical compositions for treatment of diseases.Type: GrantFiled: October 27, 1998Date of Patent: December 14, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Lynn E. Murry
-
Patent number: 5972649Abstract: The invention provides a human multiple endocrine neoplasia type 1 protein (MEND1) and polynucleotides which identify and encode MEND1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of MEND1.Type: GrantFiled: May 29, 1997Date of Patent: October 26, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Peter A. Covitz, Y. Tom Tang, Lynn E. Murry
-
Patent number: 5972658Abstract: The present invention provides a human lung growth factor variant (LGFV) and polynucleotides which identify and encode LGFV. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding LGFV and a method for producing LGFV. The invention also provides for agonists, antibodies, or antagonists specifically binding LGFV, and their use, in the prevention and treatment of diseases associated with expression of LGFV. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding LGFV for the treatment of diseases associated with the expression of LGFV. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding LGFV.Type: GrantFiled: December 5, 1996Date of Patent: October 26, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
-
Patent number: 5965423Abstract: The invention provides a human lysophospholipase (NHLP) and polynucleotides which identify and encode NHLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of NHLP.Type: GrantFiled: February 12, 1998Date of Patent: October 12, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah, Lynn E. Murry
-
Patent number: 5958699Abstract: The present invention provides a human tumor-associated Kazal inhibitor (TAKI) and polynucleotides which identify and encode TAKI. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TAKI and a method for producing TAKI. The invention also provides for agonists, antibodies, or antagonists specifically binding TAKI, and their use, in the prevention and treatment of intestinal diseases including cancer. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TAKI for the treatment of diseases associated with the expression of TAKI. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding TAKI.Type: GrantFiled: September 9, 1998Date of Patent: September 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
-
Patent number: 5948626Abstract: The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL. The invention also provides for the use of purified GIPL and its agonists in pharmaceutical compositions for the treatment of diseases associated with the abnormal or excess phospholipase activity. Additionally, the invention provides for the use of antisense molecules to gipl or inhibitors of GIPL in pharmaceutical compositions for the prevention of pregnancy or treatment of Alzheimer's disease.Type: GrantFiled: September 15, 1998Date of Patent: September 7, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Lynn E. Murry
-
Patent number: 5935812Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human GTP binding protein gamma-3 (HGPG) and HGPG itself. The invention provides for genetically engineered expression vectors, host cells containing the vector and a method for producing HGPG. The invention also provides a method for identifying pharmaceutical compositions inhibiting the expression and activity of HGPG and for the use of such compositions for the treatment of cancer. The invention also provides diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HGPG or anti-HGPG antibodies which specifically bind to HGPG in normal or diseased tissues.Type: GrantFiled: September 18, 1996Date of Patent: August 10, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
-
Patent number: 5932445Abstract: The invention provides signal peptide-containing proteins collectively designated SP, and polynucleotides which identify and encode these molecules. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing, treating, and preventing disorders associated with expression of signal peptide-containing proteins.Type: GrantFiled: November 7, 1997Date of Patent: August 3, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Janice Au-Young, Roopa Reddy, Lynn E. Murry, Preete Mathur
-
Patent number: 5914392Abstract: The present invention provides a nucleic acid sequence which identifies and encodes a novel tissue inhibitor of metalloproteinases (TIMP-4) which was isolated from cells of human uterus. The invention provides for TIMP-4 antisense molecules and genetically engineered expression vectors and host cells comprising nucleic acid sequence encoding TIMP-4. The invention also provides for purified TIMP-4; antibodies, antagonists and inhibitors which specifically bind TIMP-4; and pharmaceutical compositions and methods of treatment based on TIMP-4, its antagonists and inhibitors. The invention provides for diagnostic assays which utilize diagnostic compositions comprising nucleic acid sequences encoding to TIMP-4, or complements thereof, and antibodies which specifically bind to TIMP-4.Type: GrantFiled: July 7, 1998Date of Patent: June 22, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Lynn E. Murry
-
Patent number: 5912130Abstract: The present invention provides a nucleic acid sequence which identifies and encodes a G protein gamma subunit (gpg) which was isolated from human pituitary gland. The invention provides for genetically engineered expression vectors and host cells comprising nucleic acid sequence encoding GPG and for gpg antisense molecules. The invention also provides for purified GPG; antibodies, antagonists and inhibitors which specifically bind GPG; and pharmaceutical compositions and methods of treatment based on GPG antagonists and inhibitors. The invention provides for diagnostic assays which utilize diagnostic compositions comprising nucleic acid sequences, or complements thereof, encoding GPG, purified GPG to be used as a positive control, and antibodies which specifically bind to GPG.Type: GrantFiled: July 7, 1998Date of Patent: June 15, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Susan G. Stuart, Lynn E. Murry, Karl J. Guegler, Jeffrey J. Seilhamer
-
Patent number: 5885798Abstract: The present invention provides novel monocyte activating cytokine (MAC) and a polynucleotide encoding MAC. The invention also provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MAC. The invention also provides for the production and use of substantially purified MAC in pharmaceutical compositions for the treatment of cancer and disease of the immune system. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding MAC and antibodies which specifically bind to MAC.Type: GrantFiled: August 28, 1996Date of Patent: March 23, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Roger Coleman, Janice Au-Young, Lynn E. Murry
-
Patent number: 5876963Abstract: The invention provides a human nucleotide pyrophosphohydrolase (NTPPH-1) and polynucleotides which identify and encode NTPPH-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NTPPH-1.Type: GrantFiled: August 27, 1997Date of Patent: March 2, 1999Inventors: Peter Mitchell, Nancy Hutchinson, Michael Lawton, Holly Magna, Sue Yocum, Lynn E. Murry
-
Patent number: 5858756Abstract: The present invention provides a human lysophospholipase (NHLP) and polynucleotides which identify and encode NHLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing NHLP and for treating or preventing disorders associated with expression of NHLP.Type: GrantFiled: April 29, 1997Date of Patent: January 12, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah, Lynn E. Murry